Efbemalenograstim alfa

艾贝格司亭α

Report date: 2026/05/11 20:01:57

Base Information

Drug NameEfbemalenograstim alfa
Drug Alias Namerh G-CSF Fc Fusion Protein重组人粒细胞集落刺激因子-Fc融合蛋白Benegrastim贝格司亭rh G-CSF dimer +[10] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion protein
Mechanisms of ActionColony stimulating factor 3 receptor agonists
TargetsColony stimulating factor 3 receptor
Therapy Area/IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia +[4] 
Global Approved IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia
Approved Indications in ChinaNeutropenia
Original Approved Country/TerritoryMainland China
Original Approved Date2023/05/06
Country/TerritoryUnited StatesEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesEvive (Shanghai) Corp Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEvive Biotechnology Ireland LtdEvive Biotechnology Singapore Pte LtdApogepha Arzneimittel Gmbh +[9] 
Inactive CompaniesEvive Biotech Ltd
Active IndicationsChemotherapy-Induced Febrile NeutropeniaFebrile NeutropeniaNeutropenia +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AA18
Related LinksWikipediaDrugBankKEGG